Management of Elevated Blood Pressure on Perindopril/Indapamide 8mg/2.5mg

Assessment and Treatment Intensification

The European Society of Cardiology recommends a three-drug combination of RAS blocker + CCB + thiazide/thiazide-like diuretic when two-drug combinations fail to control blood pressure, with perindopril/indapamide 8mg/2.5mg being an effective antihypertensive regimen combining an ACE inhibitor with a thiazide-like diuretic 1
Persistence of elevated blood pressure despite perindopril/indapamide combination suggests the need for adding a third agent rather than further dose escalation of current medications, with the current dose of perindopril 8mg representing the maximum recommended dose for hypertension 1, 3

The American Heart Association recommends adding a dihydropyridine calcium channel blocker (CCB), preferably amlodipine 5-10mg daily, to create the preferred three-drug combination of RAS blocker + diuretic + CCB 1
Triple therapy with perindopril/indapamide/amlodipine has demonstrated superior blood pressure reduction compared to dual therapy in randomized controlled trials, with control rates exceeding 80% after appropriate up-titration 1

Reassess blood pressure within 2-4 weeks after adding the third agent, and monitor for potential side effects including peripheral edema (from amlodipine) and electrolyte disturbances 2
Check renal function and electrolytes 1-2 weeks after initiation, particularly if the patient has risk factors for renal impairment, and consider fixed-dose single-pill combinations to improve adherence 4, 1
For patients with comorbid conditions like diabetes or previous stroke, the addition of amlodipine to create a triple therapy is particularly beneficial for cardiovascular risk reduction 3

For most adults, target systolic BP should be 120-129 mmHg, provided the treatment is well tolerated, and if this target cannot be achieved due to side effects, aim for the lowest BP that is reasonably achievable without compromising safety 1